Allspring Global Investments Holdings LLC Has $10.03 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Allspring Global Investments Holdings LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 14.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 181,122 shares of the company’s stock after selling 29,409 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.47% of Tarsus Pharmaceuticals worth $10,029,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC grew its holdings in Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after acquiring an additional 3,379 shares during the last quarter. Creative Planning acquired a new position in shares of Tarsus Pharmaceuticals during the third quarter worth approximately $362,000. Assenagon Asset Management S.A. grew its stake in shares of Tarsus Pharmaceuticals by 7.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after purchasing an additional 77,825 shares during the last quarter. E. Ohman J or Asset Management AB increased its holdings in shares of Tarsus Pharmaceuticals by 20.5% in the third quarter. E. Ohman J or Asset Management AB now owns 46,981 shares of the company’s stock valued at $1,545,000 after purchasing an additional 8,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Tarsus Pharmaceuticals by 64.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock worth $241,000 after purchasing an additional 2,879 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 1.3 %

Shares of Tarsus Pharmaceuticals stock opened at $50.85 on Wednesday. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The business’s 50 day simple moving average is $52.06 and its 200 day simple moving average is $42.19. The firm has a market cap of $1.94 billion, a PE ratio of -13.35 and a beta of 1.01.

Analyst Ratings Changes

A number of research firms have recently weighed in on TARS. Guggenheim restated a “buy” rating on shares of Tarsus Pharmaceuticals in a research report on Monday, February 10th. Barclays boosted their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, The Goldman Sachs Group increased their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $56.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.